Overview

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Status:
Unknown status

Trial end date:
2020-12-27

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.

Phase:

Phase 1

Details

Lead Sponsor:

Shanghai Henlius Biotech

Treatments:

Antibodies
Antibodies, Monoclonal
Bevacizumab
Immunoglobulins